BC Extra | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

Nektar tumbles on bempegaldesleukin revelation   Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
BC Extra | May 3, 2019
Company News

O’Day touts cell therapies as Gilead beats on EPS

On his first earnings call as CEO of Gilead, Daniel O'Day said more M&A and deals by the bellwether within cell therapy are "fundamental and essential" as the company reported 1Q19 earnings Thursday that beat...
BC Week In Review | Apr 12, 2019
Company News

FDA approves ViiV's two-drug HIV regimen

FDA approved Viiv's Dovato dolutegravir/lamivudine for HIV-1 infection in treatment-naïve adults. The product is a once-daily, single-tablet regimen of dolutegravir and lamivudine that the company plans to launch in 2-3 weeks at a wholesale acquisition...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Extra | Mar 28, 2019
Politics & Policy

China lists 30 more overseas drugs eligible for Priority Review

China’s Drug Evaluation Center posted a second batch of drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China. Fourteen of the 30 drugs on the list...
BC Extra | Mar 26, 2019
Company News

Japan approvals include Kymriah as Japan's first CAR T therapy

Japanese regulators approved a basket of drugs on Tuesday, including the first CAR T cell therapy in Japan. Novartis AG (NYSE:NVS; SIX:NOVN) said Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Kymriah tisagenlecleucel to...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jul 27, 2018
Company News

Gilead's Yescarta beats estimates

In its 2Q18 earnings, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the consensus estimate of $59.1 million...
BC Extra | Jul 26, 2018
Company News

Gilead's Yescarta beats estimates

In its 2Q18 earnings released Wednesday, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the consensus estimate of...
Items per page:
1 - 10 of 30